Mounjaro

What is Mounjaro?

Mounjaro (tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It represents a paradigm shift in metabolic treatment by simultaneously targeting two incretin pathways.

Mechanism of Action:

• GIP Receptor Activation: Enhances insulin secretion + inhibits glucagon only during hyperglycemia

• GLP-1 Effects: Slows gastric emptying (50% reduction vs placebo) + promotes satiety

• Adipose Tissue Modulation: Upregulates lipid storage genes, reducing visceral fat

FDA-Approved Indications

✅ Type 2 Diabetes (2022):

• HbA1c reduction: 1.8-2.4% (vs 1.4% for semaglutide in SURPASS-2 trial)

• 36% achieve HbA1c <5.7% (non-diabetic range)

✅ Chronic Weight Management (2023, as Zepbound brand):

• Average weight loss: 15-22% (SURMOUNT trials)

• 37% achieve ≥25% weight loss at highest dose

Dosage & Administration

Key Distinction:

• Flexible dosing: No rigid meal timing requirements

• Auto-injector: Hidden needle design reduces anxiety